2025년 03월 29일 토요일
 
 
  현재위치 > 뉴스지닷컴 > Science & Technology

랜섬웨어부터 돼지도살까지... 노련해진 사기행각

 

정치

 

경제

 

사회

 

생활

 

문화

 

국제

 

과학기술

 

연예

 

스포츠

 

자동차

 

부동산

 

경영

 

영업

 

미디어

 

신상품

 

교육

 

학회

 

신간

 

공지사항

 

칼럼

 

캠페인
한살림 ‘우리는 한쌀림’ 쌀 소비 캠페인 시...
1000만원짜리 인공와우, 건강보험 지원 ‘평...
- - - - - - -
 

Korean Research Team Establishes World’s First Tonsil Epithelial Organoids Model for SARS-CoV-2 Infection

World’s First Tonsil Epithelial Organoids Model for SARS-CoV-2 Infection Published in Biomaterials
뉴스일자: 2022-04-06

PANGYO-- April 06, 2022 -- The research team led by Professor Jongman Yoo (Cha University and CEO of ORGANOIDSCIENCES) along with Professor Young-Chang Lim (Konkuk University) and Dr. Meehyein Kim (Korea Research Institute of Chemical Technology) successfully established tonsil epithelial cell-derived organoids and proved their feasibility as a 3D cultured infection model.

Organoids, in vitro miniaturized model systems of organs, has been positioned as the most advanced scientific technology for understanding disease progress mechanisms and for discovering novel drugs. However, the generation of tonsil organoids with high reproducibility had remained a technical challenge due to the lack of their cultural system.

This is the first research outcome to the generation of tonsil epithelial organoids, which are structurally and genetically similar to human tonsil tissues, as well as to the scientific assessment of their suitability as an ex vivo model for SARS-CoV-2.

The team showed that the organoids elicit robust expression of transmembrane serine protease 2 (TMPRSS2) and furin, which are important for the maturation of spike proteins, and of the angiotensin-converting enzyme 2 (ACE2) cell surface receptor, which is essential for SARS-CoV-2 infection.

According to the journal, when Remdesivir, an antiviral drug, was applied to tonsil organoids infected with SARS-CoV-2, both viral RNA and protein levels were remarkably reduced. It is expected that the tonsil epithelial organoid could be utilized more extensively as an antiviral drug evaluation system for translational research, particularly against SARS-CoV-2 or its variants.

The results of this study demonstrated that the organoids are an attractive infection model for testing tissue susceptibility or transmissibility of diverse gastrointestinal or respiratory viruses. They provided insight into host defense mechanisms in terms of innate and adaptive immunity in which immunological interactions occur between tonsil epithelial cells, immune cells, and SARS-CoV-2.

The research team said, “Our discovery confirmative suggests that tonsil organoids can be one of the powerful platform technologies to find an antiviral drug against this pandemic virus. We hope our result can be connected to its applications in the research area of infectious diseases threatening public health such as COVID-19.”

On the Biomaterials website, the full research ‘Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection’ can be found.



 전체뉴스목록으로

Lenovo: Current State of Workplace IT Impedes AI Productivity Benefits
Xsolla Launches Loyalty as a Service for Game Developers to Build Stronger Connections With Players
Toshiba Releases Gate Driver IC for Automotive Brushed DC Motors that Will Contribute to Downsizing of Equipment
Crown Bioscience Appoints John Gu as Chief Executive Officer
Pharmaceutical Industry Issues Call for Collective Action to Address the Rising Global Burden of Chronic Disease
NTT DATA becomes a Global Managed Service Provider in the SAP PartnerEdge, Run Program Track
Caldera Medical Acquires Ethicon’s GYNECARE TVT™ Family of Products in Transformational Expansion Globally for Women’s Health Company

 

UAE Launches Next-Gen GPS-Less Navigation and Secure Flight Control to...
50% of Asia Pacific Organizations Experience IT or Business Delays Due...
FPT Becomes Sitecore Reseller Partner, Strengthening Strategic Presenc...
Kinaxis to Unveil the Next Phase of AI Innovation at Kinexions 2025
Intersolar Europe: The Time for Hybrid Power Plants Has Come
Xsolla Cloud Gaming Expands Developer Access to New Users With Global ...
Parse Biosciences Expands Global Reach with the South Australian Genom...

 


공지사항
미디어아우어 Mediaour 媒体我们 媒體我們 MO 엠오 媒我 媒我
알리우브 Alliuv 阿备: 阿联有备, 알뜰 Althle 阿特益
알리알 Allial 중문 표기 阿利尔 阿利爾
뉴퍼스트 New1st 중문 표기 纽壹新(번체 紐壹新), N1 纽1
엔코스모스 : 이씨 'EnCosmos : EC' 중문 표기 以宙
아이디어론 Idearon 중문 표기 以迪论 以迪論
바이오이니 Bioini 중문 표기 必药研 必藥硏
오스프롬 Ausfrom 奥斯福牧, 웰프롬 Welfrom 卫福牧
에너프롬 Enerfrom 额能福牧 에너유비 Eneruv 额能有备
베네프롬 베네인투 중문 표기 宝乃福牧 宝乃因托(寶乃福牧 寶...
알프롬 Alfrom 중문 표기 阿尔福牧 阿爾福牧
뉴스지 한자 표기에 대만식 음차 표기 '纽斯集 니우시지' 병기

 

회사소개 | 인재채용 | 이용약관 | 개인정보취급방침 | 청소년보호정책 | 책임한계와 법적고지 | 이메일주소무단수집거부 | 고객센터

기사제보 이메일 news@newsji.com, 전화 050 2222 0002, 팩스 050 2222 0111, 주소 : 서울 구로구 가마산로 27길 60 1-37호

인터넷뉴스서비스사업등록 : 서울 자00447, 등록일자 : 2013.12.23., 뉴스배열 및 청소년보호의 책임 : 대표 CEO

Copyright ⓒ All rights reserved..